All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Stefano Schena, MD, PhD

HelenMari Merritt, DO
Disclosure(s): Abbott, Artivion, Atricure, Medtronic, Edwards, Terumo Aortic: Consultant (Ongoing), Speaker (Ongoing)

Presentations

1. Late Breaking: The STS 2023 Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation: Key Takeaways and How Do They Differ from the ACC/AHA Atrial Fibrillation Clinical Practice Guidelines?
   Moritz C. Wyler von Ballmoos, MD, PhD, MPH
   Disclosure(s): Medtronic: Consultant (Ongoing); Boston Scientific Corporation: Consultant (Ongoing)
    
2. Concomitant Management of AF During Cardiac Surgery: Current State and Tips to Enhance Your Practice
   Patrick M. McCarthy, MD
    
3. Left Atrial Appendage: What's Old, What's New, Is It Enough?
   Richard Whitlock, MD PhD FRCSC
   Disclosure(s): Abbott: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Artiivion Inc.: Consultant (Terminated); AtriCure, Inc.: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); CytoSorbents: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
    
4. Longitudinal Survival Advantage of Concomitant Surgical Ablation in Paroxysmal as well as Persistent Atrial Fibrillation during Mitral Valve Surgery
   Ali Darehzereshki, MD
    
5. Invited Discussant
   Ralph Damiano, Jr., MD
   Disclosure(s): Medtronic: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); AtriCure: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing); Edwards Life Science: Advisory Board (Ongoing), Speaker (Ongoing)
    
6. Hybrid Treatment of Persistent and Long-Standing AF: The CONVERGE Trial and the AF Multidisciplinary Approach
   Christian Shults, MD
   Disclosure(s): AtriCure, Inc.: Consultant (Ongoing), Speaker (Ongoing)
    
7. Panel Discussion and Audience Q&A